Increased Thromboembolic Risk With Atrial Fibrillation and Type 2 Diabetes and a Role for NOACs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review
JAMA Cardiol 2017 Jan 25;[EPub Ahead of Print], A Plitt, DK McGuire, RP GiuglianoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.